Central Airway Obstruction due to Hematologic Malignancies, Diagnosis and Local Treatment - A Narrative Review

Fantin A*, Castaldo N, Vailati P, Morana G and Patruno V
Department of Pulmonology, S. Maria della Misericordia University Hospital, Italy

*Corresponding author: Alberto Fantin, Department of Pulmonology, Santa Maria della Misericordia University Hospital, Via Colugna, 33100 Udine, Italy, Tel: +39.0432.552926; Email: af@albertofantin.com

Abstract

Background: Malignant hematologic diseases may present with rare features. One of these is the first manifestation as a central airway lesion whose symptoms could be mistaken for asthma, chronic obstructive pulmonary disease, non-resolving or recurrent pneumonia, foreign body inhalation or both acute and chronic heart failure. The age of onset of the symptoms does not help in the differential diagnosis, leaving the clinician with a diagnostic dilemma, frequently clarified by invasive sampling. Current evidence of this group of entities is based predominantly on case reports. The aim of this work is to report a non-systematic review of haematological pathologies that can present themselves as an obstruction of the central airways, the possible ways in which it is possible to diagnose and treat them locally.

Methodology: This revision work is the result of a critical analysis of the existing literature, carried out by collecting the main bibliographic entries in different languages present in international scientific databases relative to the topic of interest. All the arguments have been elaborated by the authors and critically re-proposed, in a non-systematic way (narrative revision).

Keywords: Bronchus; Bronchoscopy; Hematologic; Lymphoma; Leukaemia; Myeloma


Introduction

Malignant hematologic diseases have typical usual presentations, but unfrequently can present with rare features. One of these is the first manifestation as a central airway or endobronchial lesion (EL), whose symptoms could be mistaken for asthma, chronic obstructive pulmonary disease, non-resolving or recurrent pneumonia, foreign body inhalation or both acute and chronic heart failure [1-4]. The age of onset of the symptoms does not help in the differential diagnosis as both adult and paediatric cases have been described. [5-7]. This presentation represents a diagnostic dilemma, frequently clarified by thoracic imaging as chest X-ray or chest computed tomography scan and diagnosed by invasive techniques as bronchoscopy. Blood tests can promote diagnostic suspicion and highlight the severity of the underlying disease.
Current evidence of this group of entities is based predominantly on case reports. The purpose of this paper is to report a non-systematic review of the pathologies that can present with the morphological aspect of a central airway obstruction.

Central airway obstruction due to hematologic malignancies may develop because of:
1. a localized primary lesion derived from a parietal layer
2. direct invasion of mediastinal pathological lymphatic structures
3. direct invasion of parenchymal pathological structures
4. diffusion by the lymphatic route
5. diffusion by the haematogenous route

The characteristic aspects of radiologic imaging of an EL are [8-10]:
- Complete atelectasis of a single or multiple lung lobes
- An endoluminal exophytic lesion
- Localized narrowing of the airway lumen

The main differential diagnoses are [11-14]:
- Lung carcinoma or other malignant histotype
- Benign tumor
- Papillomatosis
- Pulmonary tuberculosis
- Fungal infection
- Sarcoidosis
- Vasculitis

**Material and Methods**

This revision work is the result of a critical analysis of the existing literature, carried out by collecting the main bibliographic entries in English, German and Spanish present in international scientific databases (Medline, PubMed, Scopus, Google Scholar), by keyword research (hematology, hematologic, lymphoma, myeloma, leukemia, myeloid, amyloid, lymphoproliferative, myeloproliferative, endobronchial, endotracheal, airway).

All the arguments have been elaborated by the authors and critically re-proposed, in a non-systematic way (narrative revision). The list of bibliographic entries, therefore, is not necessarily comprehensive but reflects the body of evidence deemed by the authors functional to the objectives of this article.

**Discussion**

**Leukaemia**

Infiltration by leukaemia cells can occur in many organs. However, the formation of a tumor mass is rare. Green et al., reported a large series of patients with leukaemia of all types; only 4 of 109 showed involvement of the bronchial mucosa [15].

Sajiai, et al. described the case of a 17-year-old farmer with no previous known diseases [16]. The patient was symptomatic for cough and fever. He had a subclavicular lymphadenopathy on physical evaluation. On chest x-ray a mediastinal mass and a pleural effusion were demonstrated. An EL contiguous to the mediastinal mass was described, which demonstrated both a compression and infiltration effect on the main bronchial branches. An endobronchial biopsy was diagnostic for a T phenotype monoclonal disease (membrane expression of anti-CD10 antibodies, anti-CD5 and anti-CD3). The study of bone marrow cytology confirmed the suspicion of T-acute lymphoblastic leukaemia.

**Hodgkin's Lymphoma**

Patients with Hodgkin's lymphoma (HL) have a 40% likelihood of pulmonary involvement. It usually presents as a solitary lung mass, cavitory lung lesion, apical lung lesion with Pancoast syndrome or widespread involvement of the lungs, but presentation as an EL is very rare [21,22]. Fewer than 100 cases of primary pulmonary HL have been described and it occurs predominantly in women with a bimodal age distribution, with the first incidence peak in the third decade, and the second being in the sixth/seventh decade [23]. A careful initial staging is necessary in order to confirm the absence of involvement of regional hilar or mediastinal lymph nodes and systemic disease.

Hoste, et al. firstly introduced in 1984 two criteria aimed at defining an endobronchial presentation of HL: 1) involvement of the lung, lobar or primary bronchus, with or without mediastinal involvement; 2) no evidence of extra-thoracic lymphoma at the time of diagnosis or for three months thereafter [24]. Instead in 1994 Tredaniel proposed two simplified criteria: 1) histopathological features consistent with Hodgkin’s disease; 2) bronchoscopy revealing endobronchial obstructing lesion [25,26].
Shazia et al. illustrated the case of a 16-year-old patient with an EL found during the investigations for the relapse of a previous known HL. Bronchoscopy revealed a necrotic endobronchial mass. The first sampling was non-diagnostic and on the basis on the strong suspicion for malignant disease, it was repeated showing CD-30 positive HL cells, underlying the need to maintain a high level of suspicion towards these kind of lesions [27]. Abid, et al. [21] described a similar case in a 40-year-old man, with concomitant HL skeletal metastasis at the time of diagnosis, stressing the importance of a complete initial staging. In a personal case (Figure 1) a mixed cellularity HL was diagnosed by endobronchial biopsy in a 60-year-old male as an EL located in the proximal sector of the right superior bronchus (non-published data). Biopsy confirmed a CD30, PAX5 e MUM1 immunoreactivity.

**Figure 1:** Endobronchial view: mucosal thickening located at the carina between the right superior bronchus and the intermediate bronchus. Mixed cellularity Hodgkin's lymphoma, Personal case.

**Non-Hodgkin's Lymphoma**

Most of the extra nodal presentations of non-Hodgkin's lymphoma (NHL) involve skin, stomach, brain, and small intestine [28]. The NHL group represents the entities with the largest volume of published evidence regarding presentation as an EL, both in the adult and paediatric age. NHL of the lung encompasses 3.6% of extra nodal lymphomas and 0.3% of primary lung neoplasms [29]. Reports vary as to how stringent the inclusion criteria for defining EL are. The most common histological subtype of primary pulmonary lymphoma (PPL) is that of indolent lymphoma mainly of mucosa-associated lymphoid tissue (MALT) type [30].

Endobronchial NHL can be divided into two types: 1) submucosal infiltrates originating from haematogenous or lymphangitic spread in the presence of systemic lymphoma; 2) adjacent airway involvement by a localized mass due to direct spread from adjacent lymph nodes [29]. Primary isolated endobronchial NHL is rare, with very few reports in the current literature. An accurate staging, considering the indication for complete blood count, bone marrow and cerebral spinal fluid evaluation, selective computed tomography, magnetic resonance imaging and skeletal scintigraphy should follow the diagnosis [31].

Endobronchial mucose-associated lymphoid tissue (MALT) lymphomas are considered to be the most frequent type of primary pulmonary lymphoma (PPL) [32]. Lymphomas of the bronchus associated lymphoid tissue (BALT) can be observed in the 25-85 year age group, often involving patients within the sixth decade of life and affecting both sexes with the same incidence [33]. The presenting thoracic CT findings have been described as three patterns: 1) solitary intraluminal nodule; 2) several tiny nodular protrusions; and 3) diffuse wall thickening [10]. Erbaycu published the case of a 32-year-old woman admitted for dyspnoea on exertion and different polyloid ELs in the left main bronchus with a diagnosis of low-grade BALT lymphoma, the patient did well with systemic therapy [34]. Hashemi presented a 61-year-old man with a localized EL in the right lower bronchus and consensual atelectasis the right lower lobe. On fiberoptic bronchoscopy, the right bronchus intermedius was completely obstructed by an easily bleeding mass. A diagnosis of BALT lymphoma was made. The surgical route was not considered, as pneumonectomy would have been indicated due to the proximity to the right main bronchus. The patient was then treated with radiotherapy (total 30 Gy), resulting in total remission of the tumour [35]. Liao described a 85-yr old woman presenting with haemoptysis, diffuse intrabronchial nodularity and responsive to rituximab therapy [36].

Hardavella, et al. illustrated the case of an 80-year-old man with a prior history of prostate cancer with a right main bronchus occlusion and mediastinal lymphadenopathy. A large mass sampled during bronchoscopy revealed a large B-cell NHL, showing how central airways malignant hematologic diseases should be taken in consideration even in older patients with a previous a previous malignancy in their medical history [37]. Other descriptions of endobronchial large B-cell NHL both as infiltration from a mediastinal mass and a primitive EL have been published by Sahin [38], Thomas [39], Solomonov [40], Zamboni [41], Sousa [42], Han [43], Meka M, et al. [44]. Argüder, et al. instead illustrated an interesting case in which a patient treated for Hodgkin’s lymphoma 18 years earlier developed a B-phenotype NHL with diffuse endobronchial distribution, which was found to be very well responsive to chemotherapy [45].

Anaplastic large cell lymphoma (ALCL) commonly presents as a nodal disease, but Bhalla described a the presentation as a lung mass with focal bronchial infiltration [5]), while Chen published a case with a primitive distal tracheal involvement treated with chemotherapy since
both upper and lower diaphragm lymph nodes and bone structures were involved at initial staging [46]. Kanthan, et al. described the case of paediatric primary ALCL, presenting as a right main bronchus lesion causing complete right lung atelectasis and firstly diagnosed as an Ewing Sarcoma. In fact, approximately 80% of ALK-positive ALCLs express CD99, an antigen also present in Ewing’s sarcoma, highlighting how the quality and quantity of the histological material must be sufficient for the pathologist to carry out all the necessary investigations [47]. An aspect to underline again for ALCL is the need to obtain sufficient tissue material in order to evaluate both the immunohistochemical aspects and the translocation state of the ALK gene, as its expression is an important prognostic factor [48]. Of peculiar interest is the report by Mikowski, describing the case of a 60-year-old man with LLC and recurring lingular pneumonia who on bronchoscopy was found to have an EL whose specimens oriented for a diagnosis of ALCL, consistent with Richter’s transformation. The mass was treated with Nd-YAG laser to restore airway patency and with subsequent chemotherapy [3].

Burkitt’s lymphoma causes some of the most aggressive manifestations of haematological disorders within the central airways. This type of lymphoma very often affects young patients, with a non-negligible percentage of HIV-positive individuals [49]. From the endoscopic point of view, they cause obstructing lesions with rapid dimensional evolution and occasional immediate risk to life. In a personal case (Figure 2) a diagnosis was made during an emergency rigid bronchoscopy for acute dyspnoea in a patient with a central airway lesion (non-published data). The obstruction was relieved using laser devascularisation followed by a coring out technique. The tissue evaluation confirmed Burkitt’s lymphoma.

![Figure 2: A: chest CT, coronal view, EL visible in the proximal trachea. B: PET-CT, axial view, showing FDG-avid tissue in the proximal trachea. C: Endotracheal view: vascularized polypoid lesion in the proximal trachea. Burkitt’s lymphoma. Personal case.](image)

Reports relating to mantle cell lymphoma (MCL) are quantitatively meager but noteworthy. The first report was proposed by Figgis [50], then Miyoshi brought to the attention the case of a 70-year-old woman whose cause of death was a rapidly progressive respiratory failure due to diffuse stenosis of the major bronchi of both lungs due to intramural and intraluminal infiltration of MCL cells [51]. This type of lymphoma presents with a diffuse distribution within the central airways, with easily bleeding lesions which are difficult to treat locally by endoscopic techniques, as reported by Katono [52].

Pulmonary T-cell lymphomas (PTLD) are more rarely described as EL. The first case was reported by Ferrer who concluded that T-cell lymphomas may present as an EL before the skin manifestations even appear [53]. Another PTLD case presented as an EL was described by Matsumoto in association with chronic pyothorax [54].

**Plasmacytoma**

Extramedullary plasmacytoma (EMP) is an uncommon condition defined by the presence of neoplastic plasma cells outside the bone marrow. It typically affects the head and neck region, and central airway involvement is very rare [55]. Bussy published the case of a 58-year old man with a history of multiple myeloma, presenting with pulmonary nodules and a central EL extended from the proximal bronchus intermedius to the right lower lobe bronchus. The biopsy suggested the tumor was of plasma cell origin with light chain restriction [56]. Local therapy for this entity has been proposed by Brackett, who performed the first documented laser treatment in an endobronchial plasmacytoma [57]. In the case exposed by LeNoir surgery was performed
due to a non-diagnostic bronchial biopsy. A mediastinal lymphadenectomy and a workup for multiple myeloma were performed too and were negative [58].

Amyloidosis

Amyloidosis is characterized by the abnormal extracellular deposition of insoluble fibril proteins. The localized form is limited to a single organ such as bladder, skin, heart, or lung [59]. Most cases of respiratory amyloidosis have been described in three forms: 1) diffuse interstitial amyloidosis; 2) nodular parenchymal amyloidosis; 3) tracheobronchial amyloidosis [60]. Most of the clinical cases in the literature were initially diagnosed as bronchial asthma [61]. Tanriverdi described the case of a 68-year-old followed for non-responsive asthma for two years. A chest CT was performed, showing a tracheal exophytic lesion. Histopathological evaluation revealed that the mass was consistent with a diagnosis of tracheobronchial amyloidosis. The patient underwent rigid bronchoscopy and the lesion was removed by mechanical resection following both Nd-YAG laser and argon plasma coagulation [60]. Lal published a similar case, initially diagnosed as bronchial asthma. Following a CT scan of the chest, bronchial thickening with calcification of the wall and moderate stenosis of the left upper lobe was reported. Fiberoptic bronchoscopy was done, which showed a yellowish colour, nodular tumor like lesion in left upper lobe bronchus. A biopsy showed pink amorphous material with green birefringence under polarized light, suggesting amyloidosis. Serum and urine electrophoresis, autoimmunity and an echocardiogram showed no significant findings and the patient was diagnosed with primary localized endobronchial amyloidosis [62]. Other reports describe a diffuse bronchial thickening as the first presentation modality [63]. Fiorelli described a case in which an endobronchial laser resection was performed for therapeutic purposes with the subsequent positioning of a self-expanding tracheo-bronchial metal stent [64].

Diagnosis

The diagnosis of central airways hematologic malignancies is a challenge in the clinical practice because symptoms and radiological findings are always non-specific. The appearance of respiratory symptoms (dry or productive cough, dyspnea, haemoptysis, chest pain or stridor) especially of subacute onset in haematological patients or with suspected haematological pathology should induce prompt evaluation with imaging techniques (chest X-ray, chest computed tomography scan, positron emission tomography) and functional respiratory tests as spirometry. Common clinical feature of haematological diseases as cervical and axillary lymphadenopathies, fever, weight loss, night sweats and recurrent infections may be presenting features as well. After careful evaluation for potential infectious aetiologies, the diagnosis for an EL has to be considered, since early intervention can be curative [65]. The presence of a radiological diagnosis of pneumonia does not exclude the presence of an EL as the infectious events are favoured by bronchial occlusion, by the immunosuppression induced by the underlying disease and by chemotherapy or immunosuppressive therapy if already started [3].

Functional respiratory test will show an obstructive functional pattern due to both focal polypoid lesions and diffuse narrowing of the bronchial lumen [18]. Once the suspicion of an EL becomes concrete, bronchoscopy allows the localization and sampling aimed at the final diagnosis. Both bronchoalveolar lavage, cytological and histological samples can be acquired in order perform tissue diagnostic tests, to look for donality and immunophenotype [66].

Local Treatment

After careful initial staging, the patient is evaluated for the indication of induction therapy or a more intensive consolidation cycle. Although hematologic diseases are frequently not considered surgically approachable, there is a role for local intervention in the management of these diseases and a consultation with the pulmonology team should be considered. Interventional pulmonology procedures are the gold standard in this setting as airway interventions offer therapeutic benefit when other modalities of treatment are limited. The goal can be both curative and palliative in order to improve quality of life, relieving dyspnoea and resolving recurrent infectious episodes.

Rigid Bronchoscopy and Laser Therapy

Bronchoscopy is the mainstay to approaching an EL under direct vision and it allows tissue sampling. Rigid bronchoscopy is a traditional procedure, which must be performed under general anaesthesia [67]. It allows complete control of the patient’s airway and allows the passage of larger instruments and cameras to diagnose and treat airway disease [68,69]. The rigid barrel of the rigid bronchoscope has a bevelled tip which allows resection of the exophytic lesions present within the airways, while ensuring a local haemostasis mechanism given by the compression of the metal body of the instrument on the mucosa [70].

Thermal laser vaporization treatment has been reported as a successful method of relieving central airway obstruction [71]. The laser beam-induced coagulation helps with the devascularisation of the lesion favouring its subsequent mechanical removal. In fact, bronchial debulking is safer and more rapid if laser therapy is combined with mechanical coring, which allows the resection of the EL, in
turn reducing the need for laser-time-exposure [72,73]. For peripheral lesions treated with a flexible bronchoscope, the laser can carbonise the lesion, which is then removed with biopsy forceps or a cryoprobe [74-76]. The evidence is stronger for non-small and small cell lung cancer, but tumor localization, morphology and respiratory symptoms are similar in endobronchial hematologic malignancies and the same treatments could be proposed if the patient is adequately informed.

**Photodynamic Therapy**

The premise of photodynamic therapy (PDT) is the selective retention of a porphyrin by tumor cells. When activated by laser light at the proper wavelength, this agent generates toxic oxygen-free radicals, which in turn cause tumor necrosis. Photodynamic therapy has been proven an effective modality for treating bronchogenic carcinoma and oesophageal carcinoma [77].

Bahram, et al. described the case of an endobronchial presentation of nodular sclerosing classic Hodgkin lymphoma, treated with PDT aimed at relieving the obstruction before induction of specific therapy [78].

**Stenting**

Endobronchial stenting is a palliative temporary or definitive solution for central airway lesions [79,80]. Stenting can be proposed as a rapid solution to progressing dyspnoea and must be associated with tumor-specific therapy. Stent removal following specific therapy must always be considered in order to improve the quality of life of the patient and mitigate the risk of stent migration after a significant response to systemic therapy, causing the shrinkage of the malignant lesion. Schmidt et al. described 5 consecutive cases in patients with malignant lymphoma who presented with severe dyspnoea. Nine stents were implanted into the trachea or main bronchi. After stenting, patients underwent tumor-specific therapy. In 4 patients (80%), stents could be removed after successful tumor-specific therapy, which led to an improvement in the size of the stenosis after an average interval of 26 days [81].

**Conclusion**

Because of the dramatic prognostic implications, an endobronchial presentation of a hematologic malignancy, despite its uncommon occurrence, should be considered in the differential diagnosis of a central airway lesion, especially in a patient with cough, haemoptysis, atelectasis, hilar, or mediastinal lymphadenopathy. Bronchoscopy and adequate tissue sampling play the central role in diagnostics. Due to the rarity of these lesions, guidelines for management are largely consensus-based rather than evidence-based and the optimal therapy remains to be determined. Before, in conjunction with or following tumor-specific therapy, palliative treatment to relieve respiratory symptoms associated with the critical airway obstruction should be undertaken at tertiary centres with experience in rigid bronchoscopy, laser therapy, and advanced endoscopic techniques.

**References**


